Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30157159 | 0.96 | BTK (0.45) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL24575642 | 0.96 | BTK (0.45) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL24575377 | 0.92 | BTK (0.45) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL31057366 | 0.92 | BTK (0.45) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL24574884 | 0.89 | PIM1 (0.43) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL31057329 | 0.89 | PIM1 (0.43) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL28934494 | 0.89 | PIM1 (0.43) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL28934282 | 0.88 | MEN1 (0.43) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL30101075 | 0.88 | MEN1 (0.43) | BTKPIM1PIM2USP30CNR1 | |
| SCHEMBL28934278 | 0.88 | MEN1 (0.43) | BTKPIM1PIM2USP30CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4375274-A1 | ANNULATED PYRIDAZINE COMPOUND | Nico Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2022135567-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | BTK 3479/4885PIM1 2985/4885PIM2 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.